dimecres, 21 de març del 2018

Genentech’s pre-filled syringe for diabetic retinopathy wins FDA nod

Lucentis from GenentechRoche‘s (OTC:RHHBYGenentech announced today that the FDA approved its 0.3-mg pre-filled syringe as a new way to administer Lucentis to diabetic retinopathy patients.

The company’s drug is the only FDA-approved medicine indicated for the treatment of diabetic retinopathy. The 0.3-mg pre-filled syringe is the first device of its kind approved to deliver an anti-vascular endothelial growth factor agent to patients with diabetic retinopathy and diabetic macular edema.

Get the full story at our sister site, Drug Delivery Business News.

The post Genentech’s pre-filled syringe for diabetic retinopathy wins FDA nod appeared first on MassDevice.



from MassDevice http://ift.tt/2u8AAIJ

Cap comentari:

Publica un comentari a l'entrada